BioWorld Asia

April 6, 2005

PharmaMar's Yondelis Phase III Trial Started In Ovarian Cancer

Taking aim at relapsed ovarian cancer patients considered incurable, Madrid, Spain-based PharmaMar SA is starting a Phase III trial with Yondelis (trabectedin), a compound first isolated from marine tunicates. (BioWorld International) Read More

Rosetta Genomics Brings In $4M For Preclinical Studies

Identifying Pre-Eclampsia Gene Could Bring Diagnostic Testing

Nautilus Biotech Gets EUR7.25M In Third Round Of Financing

Ark, Boehringer Ingelheim Form Collaboration Over IP

Syngenta Slip-Up Causes Red Faces Across European Union

Israeli Chief Scientist Designates Biotech, Nanotech High Priorities

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

In 2025, science’s biggest story was political

BioWorld

In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...

Abstract blue human heart with red cardio pulse line and red circle

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

BioWorld

Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...

Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

BioWorld Science

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....